---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-022313"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:38:33.699634+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics Q3 net loss $109.6M; BEACON trial enrollment started for BEAM-101

## Summary
- Net loss $109.6M ($1.56/sh) vs $28.1M ($0.42/sh) in Q3 2021; R&D spend $85.3M.
- Cash, cash equivalents and marketable securities $1.1B as of Sep 30, 2022, up from $965.6M.
- Patient recruitment underway in BEACON trial for BEAM-101; first sickle cell patient enrollment expected by year-end 2022.
- BEAM-302 nominated as development candidate for alpha-1 antitrypsin deficiency; targeting in vivo DNA correction of E342K mutation.
- BEAM-201 IND response submitted to FDA after clinical hold; no BEAM-102 IND filing in 2022.

## SEC filing metadata
- accession: 0000950170-22-022313
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017022022313/0000950170-22-022313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017022022313/beam-20221107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-022313
- JSON: https://secwatch.observer/filing/0000950170-22-022313.json
- Plain text: https://secwatch.observer/filing/0000950170-22-022313.txt

## Key facts
- Earnings Releases
  Beam Therapeutics Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 7, 2022, Beam Therapeutics Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000095017022022313/0000950170-22-022313-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.